CURE

FDA Fully Approves Braftovi Combo for BRAF V600E Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
ascopubs.org

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center

A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...
Nasdaq

FDA OKs Guardant360 CDx As Companion Test For BRAF V600E Metastatic Colorectal Cancer

(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...
Healio

Encorafenib combination secures FDA approval for metastatic colorectal cancer

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
Medscape

Dabrafenib-Trametinib Combo Approved for Range of Solid Tumors

The US Food and Drug Administration has granted accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for adult and pediatric patients aged 6 years and older with unresectable or ...
Cure Today

FDA Approves Tafinlar Plus Mekinist for Patients With BRAF V600-Mutant Solid Cancers

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers. The Food and Drug ...
Monthly Prescribing Reference

Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors

Illustration of intestinal carcinoma, showing malignant tumor in intestine. The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H ...
Reuters

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...
The American Journal of Managed Care

Dr Vernon Sondak on BRAF Mutations in Metastatic Melanoma

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...
Nature

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval

You have full access to this article via your institution. “Physicians should consider a BRAF test as a routine diagnostic step that could enable a new option for ...
Healthline

Non-small Cell Lung Cancer

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...